![Robert Kilkuskie](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Robert Kilkuskie
Directeur/Bestuurslid bij Michigan High Throughput Screening Center
Profiel
Robert Kilkuskie currently works at Michigan High Throughput Screening Center, as Executive Director from 2009 and National Institute of Health Policy, as Principal.
Actieve functies van Robert Kilkuskie
Bedrijven | Functie | Begin |
---|---|---|
Michigan High Throughput Screening Center
![]() Michigan High Throughput Screening Center Miscellaneous Commercial ServicesCommercial Services Michigan High Throughput Screening Center develops screening technologies for drug discovery. It offers services to academic institutions, biotechnology & pharmaceutical companies, and government laboratories. The firm is a not-for-profit contract research organization. Its scientists has extensive experience in drug discovery research and have experience in developing, validating and implementing high throughput screening assays for a broad range of drug targets in central nervous system disease, inflammation, infectious diseases, and oncology. It also has an extremely diverse library containing 100,000 drug able compounds and requires no licensing fees or royalties. | Directeur/Bestuurslid | - |
National Institute of Health Policy | Corporate Officer/Principal | 30-04-2010 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Michigan High Throughput Screening Center
![]() Michigan High Throughput Screening Center Miscellaneous Commercial ServicesCommercial Services Michigan High Throughput Screening Center develops screening technologies for drug discovery. It offers services to academic institutions, biotechnology & pharmaceutical companies, and government laboratories. The firm is a not-for-profit contract research organization. Its scientists has extensive experience in drug discovery research and have experience in developing, validating and implementing high throughput screening assays for a broad range of drug targets in central nervous system disease, inflammation, infectious diseases, and oncology. It also has an extremely diverse library containing 100,000 drug able compounds and requires no licensing fees or royalties. | Commercial Services |
National Institute of Health Policy |